Table I.
Demographics and clinical characteristics of patients on biologics and matched controls
| Demographic or clinical variable | Biologic group N = 7361 |
Matched controls N = 74,910 |
P value |
|---|---|---|---|
| Age group (years), N (%) | >.99 | ||
| 18-44 | 2783 (37.8%) | 28,321 (37.8%) | |
| 45-64 | 2838 (38.6%) | 28,881 (38.6%) | |
| 65-74 | 1135 (15.4%) | 11,550 (15.4%) | |
| ≥75 | 605 (8.2%) | 6157 (8.2%) | |
| Sex, female, N (%) | 4124 (56.0%) | 41,968 (56.0%) | >.99 |
| Race and ethnicity, N (%) | >.99 | ||
| White non-Hispanic | 6223 (84.5%) | 63,329 (84.5%) | |
| Asian or Pacific Islander non-Hispanic | 263 (3.6%) | 2676 (3.6%) | |
| Black non-Hispanic | 332 (4.5%) | 3379 (4.5%) | |
| Other non-Hispanic | 139 (1.9%) | 1415 (1.9%) | |
| Hispanic | 223 (3.0%) | 2269 (3.0%) | |
| Unknown | 181 (2.5%) | 1842 (2.5%) | |
| Charlson comorbidity index grade, N (%) | >.99 | ||
| Mild (1-2) | 4050 (55.0%) | 41,215 (55.0%) | |
| Moderate (3-4) | 1591 (21.6%) | 16,191 (21.6%) | |
| Severe (≥5) | 1720 (23.4%) | 17,504 (23.4%) | |
| Medical comorbidity, N (%) | |||
| Hypertension | 2147 (29.2%) | 21,561 (28.8%) | .49 |
| Congestive heart failure | 355 (4.8%) | 4867 (6.5%) | <.001 |
| Diabetes | 818 (11.1%) | 11,234 (15.0%) | <.001 |
| Chronic pulmonary disease | 933 (12.7%) | 10,738 (14.3%) | <.001 |
| Other pulmonary disease | 1529 (20.8%) | 17,546 (23.4%) | <.001 |
| Renal disease | 561 (7.6%) | 5797 (7.7%) | .72 |
| Liver disease | 1156 (15.7%) | 11,821 (15.8%) | .86 |
| Hematologic cancer | 593 (8.1%) | 3043 (4.1%) | <.001 |
| Solid organ cancer, not metastatic | 1270 (17.3%) | 15,949 (21.3%) | <.001 |
| Solid organ cancer, metastatic | 145 (2.0%) | 3592 (4.8%) | <.001 |
| Indication | |||
| Asthma | 1428 (19.4%) | 13,162 (17.6%) | <.001 |
| Atopic dermatitis | 2022 (27.5%) | 15,112 (20.2%) | <.001 |
| Chronic lymphocytic leukemia | 65 (0.9%) | 263 (0.4%) | <.001 |
| Non-Hodgkin lymphoma | 483 (6.7%) | 1421 (1.9%) | <.001 |
| Giant cell arteritis | 186 (2.5%) | 159 (0.2%) | <.001 |
| Granulomatosis with polyangiitis | 104 (1.4%) | 105 (0.1%) | <.001 |
| Microscopic polyangiitis | 20 (0.3%) | 6 (0.01%) | <.001 |
| Systemic lupus erythematosus | 233 (3.2%) | 521 (0.7%) | <.001 |
| Pemphigus | 32 (0.4%) | 59 (0.1%) | <.001 |
| Hidradenitis suppurativa | 166 (2.3%) | 387 (0.5%) | <.001 |
| Psoriasis | 2012 (27.3%) | 3054 (4.1%) | <.001 |
| Psoriatic arthritis | 1192 (16.2%) | 369 (0.5%) | <.001 |
| Rheumatoid arthritis | 2027 (27.5%) | 1930 (2.6%) | <.001 |
| Ankylosing spondylitis | 452 (6.1%) | 183 (0.2%) | <.001 |
| Uveitis | 211 (2.9%) | 594 (0.8%) | <.001 |
| Crohn's disease | 1829 (24.9%) | 515 (0.7%) | <.001 |
| Ulcerative colitis | 1388 (18.9%) | 1094 (1.5%) | <.001 |
| COVID-19 positive, N (%) | 87 (1.2%) | 1063 (1.4%) | .10 |
| Died, N (% of COVID-19–positive patients) | 7 (8.0%) | 71 (6.7%) | .79 |
| COVID-19 town or county positivity rate per 100 mean (SD) | 1.4 (0.9) | 1.6 (1.1) | <.001 |
| N = 7317 | N = 74,389 | ||
| Median income in $1000s mean (SD) | 82.0 (29.2) | 79.7 (29.2) | <.001 |
P values <0.05 appear in bold.